Citadel Advisors’s Lisata Therapeutics LSTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $52.8K | Sell |
15,541
-7,125
| -31% | -$25.4K | ﹤0.01% | 13088 |
|
|
2026
Q1 | $114K | Buy |
+22,666
| New | +$93.6K | ﹤0.01% | 11900 |
|
|
2025
Q1 | – | Sell |
-23,273
| Closed | -$69.4K | – | 15129 |
|
|
2024
Q4 | $69.4K | Buy |
+23,273
| New | +$66.6K | ﹤0.01% | 11984 |
|
|
2024
Q1 | – | Sell |
-14,131
| Closed | -$38.6K | – | 15107 |
|
|
2023
Q4 | $38.6K | Sell |
14,131
-4,451
| -24% | -$10.5K | ﹤0.01% | 12043 |
|
|
2023
Q3 | $38.8K | Buy |
18,582
+1,404
| +8% | +$3.9K | ﹤0.01% | 12030 |
|
|
2023
Q2 | $63.6K | Buy |
+17,178
| New | +$62.5K | ﹤0.01% | 11518 |
|
|
2023
Q1 | – | Sell |
-10,082
| Closed | -$25.1K | – | 15159 |
|
|
2022
Q4 | $25.1K | Buy |
+10,082
| New | +$37K | ﹤0.01% | 12938 |
|
|
2022
Q2 | – | Sell |
-1,203
| Closed | -$9.9K | – | 13595 |
|
|
2022
Q1 | $13K | Buy |
+1,203
| New | +$13.8K | ﹤0.01% | 13344 |
|
|
2021
Q4 | – | Sell |
-4,947
| Closed | -$76.4K | – | 14350 |
|
|
2021
Q3 | $91K | Buy |
+4,947
| New | +$97K | ﹤0.01% | 12966 |
|
|
2021
Q2 | – | Sell |
-2,881
| Closed | -$68.3K | – | 14084 |
|
|
2021
Q1 | $83K | Sell |
2,881
-2,299
| -44% | -$69.7K | ﹤0.01% | 12615 |
|
|
2020
Q4 | $111K | Buy |
5,180
+1,409
| +37% | +$33.4K | ﹤0.01% | 10157 |
|
|
2020
Q3 | $102K | Buy |
+3,771
| New | +$119K | ﹤0.01% | 9265 |
|
|
2017
Q1 | – | Sell |
-1,052
| Closed | -$45K | – | 7789 |
|
|
2016
Q4 | $45K | Buy |
+1,052
| New | +$60.4K | ﹤0.01% | 6892 |
|
|
2016
Q3 | – | Sell |
-72
| Closed | -$6K | – | 7522 |
|
|
2016
Q2 | $6K | Sell |
72
-133
| -65% | -$12.2K | ﹤0.01% | 6747 |
|
|
2016
Q1 | $23K | Buy |
+205
| New | +$20.1K | ﹤0.01% | 6433 |
|
|
2015
Q3 | – | Sell |
-15
| Closed | -$4K | – | 9080 |
|
|
2015
Q2 | $4K | Buy |
+15
| New | +$5.57K | ﹤0.01% | 8564 |
|
|
2015
Q1 | – | Sell |
-227
| Closed | -$123K | – | 8704 |
|
|
2014
Q4 | $128K | Buy |
227
+172
| +313% | +$117K | ﹤0.01% | 6424 |
|
|
2014
Q3 | $45K | Buy |
+55
| New | +$48.1K | ﹤0.01% | 6960 |
|
|
2014
Q2 | – | Sell |
-89
| Closed | -$86.5K | – | 8146 |
|
|
2014
Q1 | $94K | Buy |
+89
| New | +$96.5K | ﹤0.01% | 6258 |
|
Other funds holding LSTA
CL
Citadel Advisors's LSTA Position: Q2 2026 in Review
Citadel Advisors reduced its Lisata Therapeutics (LSTA) stake by 31% in Q2 2026, selling an estimated $25.4K and leaving 15,541 shares worth $52.8K. The position accounts for ﹤0.01% of the portfolio, ranked #13088.
Citadel Advisors first reported a position in LSTA in Q1 2014 and has held it in 19 quarters since. The position peaked at $128K in Q4 2014. 32 funds tracked by Wall St. Rank hold LSTA as of Q2 2026.
- Citadel Advisors held 15,541 shares of Lisata Therapeutics worth $52.8K as of Q2 2026.
- Citadel Advisors sold 7,125 Lisata Therapeutics shares in Q2 2026, an estimated $25.4K.
- Lisata Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13088 holding.
- Citadel Advisors first reported a position in Lisata Therapeutics in Q1 2014 and has held it in 19 quarters since.
- Citadel Advisors's Lisata Therapeutics position peaked at $128K in Q4 2014.
- 32 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.